An EZH2-NF-κB regulatory axis drives expression of pro-oncogenic gene signatures in triple negative breast cancer

[1]  M. Götte,et al.  Role of Syndecan-4 in breast cancer pathophysiology. , 2022, American Journal of Physiology - Cell Physiology.

[2]  G. Wang,et al.  A cryptic transactivation domain of EZH2 binds AR and AR’s splice variant, promoting oncogene activation and tumorous transformation , 2022, bioRxiv.

[3]  R. Roeder,et al.  EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis , 2022, Nature Cell Biology.

[4]  Yingchao Duan,et al.  Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs. , 2022, European journal of medicinal chemistry.

[5]  H. G. van der Poel,et al.  An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer , 2021, Nature Cell Biology.

[6]  L. Kiesel,et al.  microRNA‐140‐3p modulates invasiveness, motility, and extracellular matrix adhesion of breast cancer cells by targeting syndecan‐4 , 2021, Journal of cellular biochemistry.

[7]  C. Kleer,et al.  Non-canonical functions of the Polycomb group protein EZH2 in breast cancer. , 2021, The American journal of pathology.

[8]  O. Gozani,et al.  Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease , 2021, Nature Reviews Drug Discovery.

[9]  Anushya Muruganujan,et al.  The Gene Ontology resource: enriching a GOld mine , 2020, Nucleic Acids Res..

[10]  G. Wang,et al.  No Easy Way Out for EZH2: Its Pleiotropic, Noncanonical Effects on Gene Regulation and Cellular Function , 2020, International journal of molecular sciences.

[11]  Jeffrey R. Whiteaker,et al.  Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy , 2020, Cell.

[12]  K. Nephew,et al.  EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells , 2020, Cancer Research.

[13]  Sara A. Grimm,et al.  Interaction of the pioneer transcription factor GATA3 with nucleosomes , 2020, Nature Communications.

[14]  J. Rizo,et al.  A partially disordered region connects gene repression and activation functions of EZH2 , 2020, Proceedings of the National Academy of Sciences.

[15]  X. Bian,et al.  Triple-negative breast cancer molecular subtyping and treatment progress , 2020, Breast Cancer Research.

[16]  Yong Xu,et al.  Endocrinotherapy resistance of prostate and breast cancer: Importance of the NF‑κB pathway (Review). , 2020, International journal of oncology.

[17]  A. Hoffmann,et al.  Dissecting the Regulatory Strategies of NF-κB RelA Target Genes in the Inflammatory Response Reveals Differential Transactivation Logics , 2020, Cell reports.

[18]  R. Margueron,et al.  Drugging histone methyltransferases in cancer. , 2020, Current opinion in chemical biology.

[19]  O. Elemento,et al.  Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. , 2020, Cell reports.

[20]  Jun Yao,et al.  CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer , 2019, Nature Communications.

[21]  J. Winter,et al.  Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors , 2019, Clinical Cancer Research.

[22]  Steven L Salzberg,et al.  Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype , 2019, Nature Biotechnology.

[23]  Laura E. Herring,et al.  Degradation of Polycomb Repressive Complex 2 with an EED-targeted Bivalent Chemical Degrader , 2019, bioRxiv.

[24]  L. Yu,et al.  Selected lipid-based transfection reagents activate NF-κB and MAP kinases signaling pathways, induced cytokines mRNA expression in human THP-1 macrophage. , 2019, Analytical biochemistry.

[25]  K. Helin,et al.  Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation. , 2019, Molecular cell.

[26]  Bin Liu,et al.  Dynamics of breast cancer relapse reveal late recurring ER-positive genomic subgroups , 2019, Nature.

[27]  J. Licht,et al.  Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator , 2018, Cell reports.

[28]  T. Owa,et al.  Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. , 2018, The Lancet. Oncology.

[29]  Adrian V. Lee,et al.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.

[30]  M. Karin,et al.  NF-κB, inflammation, immunity and cancer: coming of age , 2018, Nature Reviews Immunology.

[31]  K. Horie-Inoue,et al.  TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling , 2017, International journal of molecular sciences.

[32]  G. Rücker,et al.  Clinical relevance of Cyr61 expression in patients with hormone-dependent breast cancer. , 2017, Oncology letters.

[33]  Icgc,et al.  Pan-cancer analysis of whole genomes , 2017, bioRxiv.

[34]  Jun Guo,et al.  The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. , 2017, Nature chemical biology.

[35]  Geet Duggal,et al.  Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference , 2017, Nature Methods.

[36]  A. Mencalha,et al.  NF-kappaB Is Involved in the Regulation of EMT Genes in Breast Cancer Cells , 2017, PloS one.

[37]  J. Balko,et al.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.

[38]  A. Baldwin,et al.  Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer , 2016, PloS one.

[39]  Jian Jin,et al.  Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors. , 2016, Journal of medicinal chemistry.

[40]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[41]  Simon Mitchell,et al.  Signaling via the NFκB system , 2016, Wiley interdisciplinary reviews. Systems biology and medicine.

[42]  J. Parker,et al.  An oncogenic Ezh2 mutation cooperates with particular genetic alterations to induce tumors in mice and redistributes H3K27 trimethylation throughout the genome , 2016, Nature medicine.

[43]  G. Stein,et al.  Oncofetal Epigenetic Bivalency in Breast Cancer Cells: H3K4 and H3K27 Tri‐Methylation as a Biomarker for Phenotypic Plasticity , 2016, Journal of cellular physiology.

[44]  Sara A. Grimm,et al.  GATA3-dependent cellular reprogramming requires activation-domain dependent recruitment of a chromatin remodeler , 2016, Genome Biology.

[45]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[46]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[47]  Xu Wang,et al.  Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[48]  Jun Yao,et al.  Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. , 2015, American journal of translational research.

[49]  Luca Pinello,et al.  Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions. , 2015, Molecular cell.

[50]  B. Garcia,et al.  Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. , 2014, Blood.

[51]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[52]  Feng Xu,et al.  An introduction to the wound healing assay using live-cell microscopy , 2014, Cell adhesion & migration.

[53]  E. Chan,et al.  Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. , 2013, Chemistry & biology.

[54]  H. Ryoo,et al.  SMURF1 Plays a role in EGF-induced breast cancer cell migration and invasion , 2013, Molecules and cells.

[55]  J. Schmid,et al.  The complexity of NF-κB signaling in inflammation and cancer , 2013, Molecular Cancer.

[56]  Anushya Muruganujan,et al.  Large-scale gene function analysis with the PANTHER classification system , 2013, Nature Protocols.

[57]  D. Nam,et al.  Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. , 2013, Cancer cell.

[58]  G. Mills,et al.  Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. , 2013, Cancer research.

[59]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[60]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[61]  A. Baldwin,et al.  Canonical and Non-Canonical NF-κB Signaling Promotes Breast Cancer Tumor-Initiating Cells , 2013, Oncogene.

[62]  M. Loda,et al.  EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.

[63]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[64]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[65]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[66]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[67]  S. Smale.  Dimer‐specific regulatory mechanisms within the NF‐κB family of transcription factors , 2012, Immunological reviews.

[68]  Qiang Yu,et al.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. , 2011, Molecular cell.

[69]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[70]  A. Chase,et al.  Aberrations of EZH2 in Cancer , 2011, Clinical Cancer Research.

[71]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[72]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[73]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[74]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[75]  D. Reinberg,et al.  Role of the polycomb protein EED in the propagation of repressive histone marks , 2009, Nature.

[76]  S. Ghosh,et al.  The NF-kappaB family of transcription factors and its regulation. , 2009, Cold Spring Harbor perspectives in biology.

[77]  J. Inoue,et al.  Constitutive activation of nuclear factor‐κB is preferentially involved in the proliferation of basal‐like subtype breast cancer cell lines , 2009, Cancer science.

[78]  G. Hannon,et al.  Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells , 2009, Cell.

[79]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[80]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[81]  G. Sonenshein,et al.  Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2 , 2007, Nature Cell Biology.

[82]  O. Halvorsen,et al.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  M. Hung,et al.  Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3 , 2005, Science.

[84]  P. Romeo,et al.  RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[86]  J. Hsieh,et al.  Down-regulation of Human DAB2IP Gene Expression Mediated by Polycomb Ezh2 Complex and Histone Deacetylase in Prostate Cancer* , 2005, Journal of Biological Chemistry.

[87]  Yi Zhang,et al.  SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. , 2004, Molecular cell.

[88]  D. Reinberg,et al.  Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. , 2004, Genes & development.

[89]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[90]  S. Ghosh,et al.  RelB Forms Transcriptionally Inactive Complexes with RelA/p65* , 2003, Journal of Biological Chemistry.

[91]  R. Lupu,et al.  Cyr61 promotes breast tumorigenesis and cancer progression , 2002, Oncogene.

[92]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[93]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[94]  G. Bren,et al.  RelB Cellular Regulation and Transcriptional Activity Are Regulated by p100* , 2002, The Journal of Biological Chemistry.

[95]  G. Bren,et al.  Transcription of the RelB gene is regulated by NF-κB , 2001, Oncogene.

[96]  M. Surani,et al.  The Polycomb-Group GeneEzh2 Is Required for Early Mouse Development , 2001, Molecular and Cellular Biology.

[97]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[98]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[99]  O. Kallioniemi,et al.  Molecular cytogenetic analysis of 11 new breast cancer cell lines , 1999, British Journal of Cancer.

[100]  S. Merajver,et al.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[101]  J. Azizkhan,et al.  Induction of NF-kappa B DNA-binding activity during the G0-to-G1 transition in mouse fibroblasts , 1991, Molecular and cellular biology.

[102]  U Zabel,et al.  DNA binding of purified transcription factor NF-kappa B. Affinity, specificity, Zn2+ dependence, and differential half-site recognition. , 1991, The Journal of biological chemistry.

[103]  R. Roeder,et al.  Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[104]  C. Reynolds,et al.  Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness. , 2022, American journal of cancer research.

[105]  W. Liao,et al.  CHPF promotes malignancy of breast cancer cells by modifying syndecan-4 and the tumor microenvironment. , 2021, American journal of cancer research.

[106]  M. Djamgoz,et al.  Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. , 2018, Cancer treatment reviews.

[107]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[108]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[109]  Shao-Cong Sun,et al.  Non-canonical NF-κB signaling pathway , 2011, Cell Research.

[110]  Charles A Tilford,et al.  Gene set enrichment analysis. , 2009, Methods in molecular biology.